(TNGX) Tango Therapeutics, Inc. Business Model Canvas Research

Biomarker and genomics partners help Tango Therapeutics, Inc. find MTAP-deleted tumors, which occur in about 15% of cancers, plus BRCA-mutant and STK11-mutant cases. Genomic testing drives patient selection, so these ties improve target validation and make trial enrollment tighter and faster.

• MTAP loss: about 15% of cancers
• BRCA and STK11 guide enrollment
• Testing boosts trial enrichment

Academic and translational research institutions give Tango Therapeutics, Inc. deeper discovery biology and synthetic-lethal insight, which helps validate targets like PRMT5 and USP1 beyond its internal team. In 2025, this kind of external science support remained key to building stronger mechanistic evidence before the next preclinical and clinical steps.

• Supports target validation
• Deepens PRMT5 and USP1 evidence
• Expands research beyond internal teams

Tango Therapeutics, Inc. advances drug candidates through IND-enabling studies and into human trials, where the main readouts are safety, dose finding, and early efficacy. This step is mandatory before commercialization, and it is where most assets either gain clinical proof or stop.

• IND-enabling studies first
• Safety and dosing next
• Early efficacy de-risks launch

Tango Therapeutics, Inc. keeps the Gilead alliance active and uses new deal-making to fund R&D, validate targets, and widen reach. In 2025, this kind of external partnering remained a core growth lever as the Company paired internal programs with partner capital and expertise.

Partnerships also lower development risk and can speed access to new oncology markets.

• Gilead alliance supports funding and validation
• New collaborations extend commercial reach
• Deal-making is part of growth

Tango Therapeutics, Inc.'s USP1 inhibitor program targets BRCA1/2-mutant cancers, tying directly to its DNA-repair strategy. It broadens the pipeline beyond PRMT5 biology and adds a second mechanistic pillar to its precision-oncology platform.

• BRCA1/2-mutant cancer focus
• Expands beyond PRMT5
• Strengthens DNA-repair franchise

Tango Therapeutics, Inc.’s scientific team is a core resource: internal researchers convert cancer-genotype data into target ideas, then chemistry into drug candidates. In a field where each program can take years and millions of dollars, human expertise is what keeps the platform moving from biology insight to clinic-ready assets.

• Genotype-to-target discovery

• In-house chemistry expertise

• Specialized human judgment

Target 3 extends Tango Therapeutics, Inc. into STK11-mutant cancers, a genetically defined group with high unmet need; STK11 alterations are seen in about 15% to 20% of non-small cell lung cancers, and they are linked to poor response and worse outcomes. It also becomes the third mutation-driven program in Tango Therapeutics, Inc.s pipeline.

• STK11-mutant cancers are hard to treat
• About 15% to 20% in NSCLC
• Third mutation-led program

Small-molecule drugs fit Tango Therapeutics, Inc.’s model because many can be taken by mouth and made at scale, which lowers dose burden for long oncology use. They also work well in combination regimens, a key setup in cancer care where multi-drug therapy is standard across many solid tumors.

• Oral dosing supports chronic use.
• Scale manufacturing can cut cost.
• Pairs well with combo therapy.

Tango Therapeutics, Inc. keeps a formal, ongoing line with regulators because biotech trials depend on clear feedback on dosing, endpoints, and safety monitoring. For a company advancing multiple oncology programs, each protocol change or dose step must line up with FDA rules, so these reviews directly shape trial speed and risk.

• Formal regulator feedback shapes trial design.
• Dosing and safety checks stay under review.
• Protocol changes need written approval.

Tango Therapeutics, Inc. keeps regular contact with capital markets and the scientific community, with pipeline updates tied to trust in a public biotech. In 2025, this mattered because investors were tracking clinical progress, cash use, and data timing across its oncology programs.

• Regular investor updates support trust
• Scientific talks help validate pipeline data
• Pipeline progress is the key signal

Tango Therapeutics, Inc. uses earnings calls, SEC filings, and investor decks to explain pipeline updates, cash runway, and capital needs. For a public biotech, this channel is critical because R&D spending and trial milestones can move fast, and investors track each 10-Q, 10-K, and quarterly call for funding risk.

• Shares pipeline progress and cash needs
• Uses 10-Q, 10-K, and earnings calls
• Key channel for public biotech trust

Medical and biomarker testing networks are a core enrollment channel for Tango Therapeutics, Inc. Genomic testing can screen for mutation-defined patients at scale, since modern next-generation sequencing panels often analyze 300+ cancer genes in one run, which helps match trial criteria faster. This channel matters because precision oncology trials need the right biomarker-positive patients, not just any patients.

• Enables mutation-based prescreening
• Speeds precision trial enrollment
• Improves match rates for eligible patients

Target 3 serves patients with STK11-mutant tumors, a mutation-defined oncology niche that is especially common in non-small cell lung cancer, which accounts for about 85% of lung cancer cases. STK11 alterations are seen in roughly 15% of non-small cell lung cancer, making this a clear biomarker-led segment for Tango Therapeutics, Inc.’s precision approach.

• Mutation-defined patient pool
• Strong fit for precision oncology
• High unmet need in STK11 disease

Oncologists and cancer centers are Tango Therapeutics, Inc.’s gatekeepers for trial adoption and patient referral: they judge whether a therapy is clinically useful, then route eligible patients into studies and future use. In the U.S., the American Cancer Society projected 2,041,910 new cancer cases in 2025, so even small gains in trust and referral flow can shape access at scale.

• Drive trial enrollment and referrals
• Assess clinical utility and safety
• Enable development and later adoption

General and administrative expenses are Tango Therapeutics, Inc.'s fixed overhead for public-company compliance, finance, legal, and HR, plus Cambridge HQ occupancy and support costs. In FY2025, this cost base remained a necessary operating layer, even as the company focused spending on research and pipeline work.

• SEC, finance, legal, HR
• Cambridge HQ occupancy
• Required for operations

Tango Therapeutics, Inc. uses CROs, consultants, and other vendors for discovery and trials, so some fixed lab and clinical costs become variable. That setup lets Tango Therapeutics, Inc. scale programs faster without building every capability in-house; in 2024, research and development still dominated spending, at about 88% of total operating expenses.

• Uses CROs for trial execution
• Buys specialist advice as needed
• Turns fixed costs into variable costs
• Scales programs without big hires

Tango Therapeutics, Inc. is still a development-stage biotech, so equity financing remains a key revenue stream: public share sales fund R&D, biomarker work, and clinical trials before any product sales arrive. That matters because the company had no product revenue and depends on external capital to keep programs moving.

• Funds research and trials
• Covers pre-revenue operations
• Reduces near-term cash stress

Tango Therapeutics, Inc. has no marketed oncology product today, so product sales are not part of the base-case model. If one pipeline asset wins approval, direct sales could become the company’s largest and most scalable long-term revenue stream, since a single oncology launch can address large patient populations across multiple tumor types.

• Current product revenue: none
• Base case: no commercial oncology sales
• Approval would create scalable direct sales